Just a few weeks after Aratana Therapeutics Inc. filed an application to the Food and Drug Administration in hopes of receiving its first FDA-approved drug, the company announced Wednesday that it's heading to Europe for another approval.
The pet therapeutics company (Nasdaq: PETX) filed a Marketing Authorization Application with the European Medicines Agency (EMA) for the drug Galliprant, the same drug waiting to be approved by the FDA.
Galliprant aims to help control the pain and inflammation…Just a few weeks after Aratana Therapeutics Inc. filed an application to the Food and Drug Administration in hopes of receiving its first FDA-approved drug, the company announced Wednesday that it's heading to Europe for another approval.
The pet therapeutics company (Nasdaq: PETX) filed a Marketing Authorization Application with the European Medicines Agency (EMA) for the drug Galliprant, the same drug waiting to be approved by the FDA.
Galliprant aims to help control the pain and inflammation…